Entia Biosciences Announces Ergothioneine Study Results
SHERWOOD, OR / ACCESSWIRE / September 30, 2014 / Entia Biosciences, Inc. (ERGO), an emerging leader in the field of nutrigenomics, today announced the publication of a study demonstrating the antioxidant and cytoprotective effects of Ergothioneine. The study, titled Uptake and Protective Effects of Ergothioneine in Human Endothelial Cells*, was published in the September 2014 issue of The Journal of Pharmacology and Experimental Therapeutics.
"The study demonstrates the effectiveness of Ergothioneine in preventing the development of endothelial dysfunction in experimental diabetes," said Entia Biosciences Inc. Chairman and CEO Dr. Marvin Hausman, MD. "Endothelial dysfunction is a condition that affects the inner lining of blood vessels and contributes to high blood pressure, diabetes, hardening of the arteries, and heart disease. Where Vitamin C, Vitamin E, and other antioxidants have failed, Ergothioneine could provide a valuable alternative, given its lack of toxicity, high potency, and broad spectrum antioxidant properties, together with high water solubility and stability at physiological pH."
In addition to Ergothioneine's potential in treating diabetes, researchers indicated that the compound could be used for the treatment and/or prevention of cardiovascular diseases associated with oxidative stress. Entia Biosciences believes that the genetically-required nutrients found in its ErgoD2(r) line of products, including L-Ergothioneine and Ergocalciferol (Vitamin D2), may play a major role in preventing the onset and/or slowing progression of these and other types of diseases, including neurodegenerative, kidney, and skin conditions. ErgoD2(r) is a proprietary pharmaceutical-grade organic compound from a whole food, in which nutrients are naturally enhanced and concentrated to therapeutic levels using Entia's patented technology.
The authors also stated that the uptake and activity of Ergothioneine involves a cellular transport system, called OCTN1 or SLC22A4. Entia Biosciences holds patents for SLC22A4 in United States, Canada, and Israel, with patents pending in the EU. These patents will be instrumental for Entia's ongoing development of ErgoD2(r) medical foods and dietary supplements.
*Rachel W. S. Li, C. Yang, Albert S. M. Sit, Y. W. Kwan, Simon M. Y. Lee,
Maggie P. M. Hoi, S. W. Chan, Marvin Hausman, Paul M. Vanhoutte, and George P. H. Leung. Uptake and Protective Effects of Ergothioneine in Human
Endothelial Cells. J Pharmacol Exp Ther 350:691–700, September 2014
About Entia Biosciences, Inc.
Entia Biosciences, Inc. (ERGO) is an authority on the clinical effects of oxidative stress and free radical reactions and is bringing this expertise to the fields of food science biotechnology and Nutrigenomics. The Company identifies, scientifically validates, patents, and commercializes solutions that address multi-billion dollar markets for health, beauty and agriculture. For more information, please visit Entia's website at www.entiabio.com.
Forward-Looking Statements
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Entia Biosciences with the Securities and Exchange Commission. Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year ended December 31, 2013 and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Entia does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
CONTACT:
Devin Andres
Chief Operating Officer
Entia Biosciences Inc.
13565 SW Tualatin-Sherwood Rd.
Sherwood, OR 97140
(503) 334-3575
SOURCE: Entia BioSciences
